Total
0
Shares
Acrux (ASX:ACR) - Managing Director & CEO, Michael Kotsanis - The Market Herald
Managing Director & CEO, Michael Kotsanis
Source: Acrux
  • Acrux (ACR) is pushing ahead with its $2 million share purchase plan (SPP) by sending off a booklet to shareholders
  • The pharmaceutical company first flagged plans to raise funds back in December, when it successfully netted $7.8 million via a placement
  • ACR plans to use all of the funds raised from the capital raises to commercialise its current and future product pipeline as well as for working capital
  • Under this latest offer, the SPP, shareholders are being offered up to $30,000 worth of shares at 15.7 cents each
  • That's the same price offered under the placement and represented a 10 per cent discount to the share price on December 4
  • The SPP opened on Friday and at this stage is set to close on January 29, before new shares are issued on February 3
  • Shares in Acrux are trading down 3.03 per cent at 16 cents each

Acrux (ACR) is pushing ahead with its planned share purchase plan (SPP) by sending off a booklet to eligible shareholders.

The pharmaceutical company first flagged plans to carry out a fundraise back in late-December, when it successfully netted $7.8 million via a placement.

ACR is now hoping to raise an additional $2 million in funds via the SPP, with shareholders invited to subscribe for up to $30,000 worth of ACR shares.

The shares under the offer are priced at 15.7 cents each — the same price offered under Acrux's recent placement.

That price also represents a 10 per cent discount to the 30-day volume-weighted average price on and up to December 4.

All of the funds raise under the SPP and Placement will be used by ACR to commercialise its current and future product pipeline as well as for working capital.

Acrux opened the plan on Friday and has slated for the SPP to close on January 29, before the new shares are then issued on February 3.

Shares in ACR have ended Friday's session down 3.03 per cent, trading at 16 cents each.


Subscribe


ACR by the numbers
More From The Market Herald
Cyclopharm (ASX:CYC) - Managing Director and CEO, James McBrayer (right) - The Market Herald

" Cyclopharm (ASX:CYC) progresses U.S. FDA approval for Technegas

Cyclopharm (CYC) has announced its Technegas product is on track to receive United States Food and Drug Administration (FDA) approval in the first
Orthocell (ASX:OCC) - Managing Director, Paul Anderson - The Market Herald

" U.S. FDA clears Orthocell’s (ASX:OCC) CelGro product

Orthocell (OCC) has received Food and Drug Administration (FDA) 501K approval to supply and market its medical collagen product CelGro in the U.S.
Noxopharm (ASX:NOX) - Chief Executive Officer, Dr Graham Kelly - The Market Herald

" Noxopharm (ASX:NOX) cleared to up dosage in COVID study

Noxopharm (NOX) has been cleared to up the dosage of its COVID-19 Veyonda treatment and progress to the final stages of the dose
MGC Pharmaceuticals (ASX:MXC) - Global Chief Sales Officer, Nicole Godresse - The Market Herald

" MGC Pharmaceuticals (ASX:MXC) appoints Nicole Godresse as Global Chief Sales Officer

MGC Pharmaceuticals (MXC) has appointed Nicole Godresse as Global Chief Sales Officer, effective immediately.